Accellix aims to enable cell and gene therapy companies to meet their key product QC requirements by providing fast and actionable multi-parameter results using the Accellix instrument and a room temperature stable cartridge.
Accellix will continue to identify markets where its platform and assay migration expertise can be best combined to create meaningful opportunities.
Accellix will continue to identify markets where its platform and assay migration expertise can be best combined to create meaningful opportunities.
Location: United States, California, San Jose
Employees: 11-50
Total raised: $9.5M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | BroadOak C... | broadoak.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.06.2020 | Series D | $9.5M | - |
Mentions in press and media 2
| Date | Title | Description |
| 13.12.2021 | Accellix Raises $10 Million From BroadOak Capital Partners | Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the manufacturing floor and at the point-of-need, today announced that it has raised... |
| 11.06.2020 | Accellix Raises $9.5M in Series D Funding | Accellix, a San Jose, CA and Jerusalem, Israel-based cell therapy QC company, raised $9.5M in Series D funding. The round was led by bioMérieux, with participation from existing major investors, who have also agreed to convert their pre-exi... |